Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy.

ABSTRACT:

Importance

Patients with advanced soft-tissue sarcomas (STS) have a median overall survival of less than 18 months. Identification of molecular abnormalities for which targeted therapies are available or can be developed is critical for improving patient outcomes.

Objective

To characterize targetable genomic alterations (GAs) in patients with STS.

Design, setting, and participants

This cross-sectional study of next-generation sequencing results from 584 patients with STS included in the AACR GENIE Database.

Main outcomes and measures

Presence of targetable GAs in STS.

Results

Of 584 patients included in the analysis, 294 (50.3%) were men and 290 (49.7%) were women, with a median age of 56 years (range, 18-89 years). There were 331 (57%) patients with com

SUBMITTER: Lucchesi C 

PROVIDER: S-EPMC6233783 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature